masitinib   Click here for help

GtoPdb Ligand ID: 5656

Synonyms: AB-1010 | AB1010 | Masican® (proposed trade name)
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Using the trade name Masivet, this compound has been used for several years to treat mast cell tumours in dogs [6]. It is a receptor tyrosine kinase (RTK) inhibitor, with inhibitory activity at the cKIT, platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR) RTKs [4].

SARS-CoV-2: Using X-ray crystallography, masitinib has been shown to bind (non-covalently) into the catalytic site of the SARS-CoV-2 3CL protease (Mpro) [3], which corresponds with detection of in vitro Mpro inhibitory activity. It does not bind to the other viral protease PLpro.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 101.63
Molecular weight 498.22
XLogP 3.41
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C
Isomeric SMILES CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C
InChI InChI=1S/C28H30N6OS/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32)
InChI Key WJEOLQLKVOPQFV-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
The European Medicines Agency has granted masitinib orphan designation as a treatment for pancreatic cancer, amyotrophic lateral sclerosis (ALS, a.k.a. motor neurone disease, MND) and mastocytosis. It has been evaluated in clinical trials for a number of inflammatory conditions, solid tumours, multiple myeloma, ALS and Alzheimer's disease. Click here to link to ClinicalTrials.gov's complete listing of masitinib trials (note that many of these are not active or have been terminated). In June 2021, a Phase 3 study testing the safety and effectiveness of masitinib as an add-on treatment to riluzole for ALS was announced by AB Science.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02588677 Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3 Interventional AB Science
NCT03127267 Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients Phase 3 Interventional AB Science